Zymeworks (ZYME) Non-Current Deferred Tax Liability (2021 - 2026)
Zymeworks (ZYME) posted Non-Current Deferred Tax Liability of $3.8 million for Q1 2026, down 36.51% sequentially from $6.0 million in Q4 2025, and down 20.52% YoY from $4.8 million in Q1 2025.
Analysis
Zymeworks (ZYME) Non-Current Deferred Tax Liability (2021 - 2026) Analysis & Trends
Zymeworks has reported Non-Current Deferred Tax Liability for 6 years, with the latest figure at $3.8 million in Q1 2026.
- Quarterly Non-Current Deferred Tax Liability fell 20.52% year-over-year to $3.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.8 million (down 20.52% YoY) and the FY2025 annual result came in at $6.0 million, down 35.91% from the prior year.
- Non-Current Deferred Tax Liability slipped to $3.8 million in Q1 2026 per ZYME's latest filing, from $6.0 million in the prior quarter.
- Over five years, Non-Current Deferred Tax Liability peaked at $13.0 million in Q4 2023 and troughed at $1.6 million in Q3 2022.
- A 5-year average of $4.4 million and a median of $3.5 million in 2024 frame the typical range for Non-Current Deferred Tax Liability.
- The sharpest annual moves came in 2023 and 2025: Non-Current Deferred Tax Liability soared 627.63% in 2023, then tumbled 35.91% in 2025.
- Over 5 years, Non-Current Deferred Tax Liability stood at $1.8 million in 2022, then jumped by 627.63% to $13.0 million in 2023, then declined by 27.7% to $9.4 million in 2024, then sank by 35.91% to $6.0 million in 2025, then slumped by 36.51% to $3.8 million in 2026.
- According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $3.8 million, $6.0 million, and $4.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 10 | Zymeworks | 2.15 Bn | 1.88 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3.74 Mn |
| Mar 31, 2026 | 3.83 Mn |
| Dec 31, 2025 | 6.03 Mn |
| Sep 30, 2025 | 4.77 Mn |
| Jun 30, 2025 | 4.85 Mn |
| Mar 31, 2025 | 4.82 Mn |
| Dec 31, 2024 | 9.41 Mn |
| Sep 30, 2024 | 3.46 Mn |
| Jun 30, 2024 | 3.40 Mn |
| Mar 31, 2024 | 3.35 Mn |
| Dec 31, 2023 | 13.01 Mn |
| Sep 30, 2023 | 1.97 Mn |
| Jun 30, 2023 | 1.92 Mn |
| Mar 31, 2023 | 1.86 Mn |
| Dec 31, 2022 | 13.27 Mn |
| Sep 30, 2022 | 1.59 Mn |
| Dec 31, 2021 | 14.10 Mn |